AIRWAYS-3
AIRWAYS-3: Randomised trial of a supraglottic airway device versus tracheal intubation during in-hospital cardiac arrest
The trial is recruiting, and continuing to set up new sites.
LATEST NEWS
Cardiac Arrest CPD Webinar Instalment 3, 22nd January 2024 - Watch the recording HERELink opens in a new window
MANDATORY TRAINING AND TRAINING LOG MUST BE COMPLETED BY ALL SITE STAFF - AIRWAYS-3 Training
Trial Design
This is a multi-centre, open-label, pragmatic, individually randomised, parallel group, superiority trial and economic evaluation to determine the clinical and cost effectiveness of SGA versus TI during IHCA. The trial will be conducted in the acute setting in NHS hospitals throughout the UK.
An internal pilot study will confirm the feasibility of the trial. An integrated economic evaluation will assess the cost-effectiveness of SGA compared with TI.
The primary outcome is the Modified Rankin Scale (mRS) score assessed at hospital discharge or 30 days following IHCA, whichever occurs sooner.
Chief Investigator: Professor Jonathan Benger
Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust
Funder: National Institute for Health Research
Registration Number: ISRCTN17720457
Summary: Randomised trial of the clinical and cost effectiveness of a supraglottic airway device versus intubation during in-hospital cardiac arrest (Airways3)
The best way to keep a person’s airway open during a cardiac arrest has been thought to be placing a breathing tube in the windpipe (tracheal intubation). However, attempting to place a breathing tube can cause complications such as accidental placement in the oesophagus (food pipe) rather than the airway, tissue damage and interruptions in chest compressions.
It is possible that a newer method of airway management, inserting a supraglottic airway device, is better than tracheal intubation during cardiac arrest. Supraglottic airway devices are already used during routine anaesthesia in hospital; in emergency care, they are quicker to insert and cause less interruption to chest compressions.
Sample size:
4190 participants
Primary outcome:
Functional status at hospital discharge (or 30 days post-randomisation whichever is shorter) as measured by the modified Rankin Scale (mRS).
Duration:
Due to the pressures on car parking capacity on campus it is not possible to provide dedicated parking for students. Students can access Pay-and-Display spaces and Pay-on-Foot car parks.Further information about parking on campus.
Recruiting and sites in set up
43 sites open
Contact Trial Team
Email:
Address:
AIRWAYS-3 Trial Team
Warwick Clinical Trials Unit,
Warwick Medical School,
University of Warwick,
Coventry.
CV4 7AL
CTU Trial Team Members
Trial Manager - Chloe Norman
Trial Co-ordinator - Jannat Chowdhury
Data Entry Clerk - Laurilee Sprauve
